New drug may help cancer patients avoid chemo delays due to low platelets

NCT ID NCT05772546

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 28 times

Summary

This phase 2 study tests whether avatrombopag, a drug that boosts platelet production, can safely and effectively treat persistent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. About 60 adults will receive either avatrombopag or a placebo. The goal is to see if the drug can raise platelet levels enough to allow patients to continue their chemotherapy without delays or dose reductions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02215, United States

  • Oregon Health and Science University Hospital

    Portland, Oregon, 97239, United States

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • University of Washington Fred Hutchinson Cancer Center

    Seattle, Washington, 98195, United States

Conditions

Explore the condition pages connected to this study.